• Je něco špatně v tomto záznamu ?

Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations

V. Holubova, R. Barone, S. Grunewald, M. Tesařová, H. Hansíková, J. Augustínová, J. Sykut-Cegielska, F. De Nictolis, U. Diaz-Moreno, R. Elangovan, F. Epifani, S. Gasperini, M. Jansen, D. Lefeber, D. Maksym-Gasiorek, M. Diego, K. Ounap, F....

. 2025 ; 48 (1) : e12826. [pub] 20241205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002858

Grantová podpora
AZV MZ CR NU22-07-00474 Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 64165 Všeobecná Fakultní Nemocnice v Praze
lékařská fakulta Univerzity Karlovy COOPERATIO-Pediatrics
PI14/00021 Ministerio de Ciencia e Innovación
PI21/00068 Ministerio de Ciencia e Innovación
FI22/00218 Ministerio de Ciencia e Innovación
G049220N Fonds Wetenschappelijk Onderzoek
Fundamenteel Klinisch Mandaat 18B4322N Fonds Wetenschappelijk Onderzoek
PRG471 Eesti Teadusagentuur
PRG2040 Eesti Teadusagentuur
Prot. 202255RLB4 Agenzia Italiana del Farmaco, Ministero della Salute

Cardiac involvement (CI) in phosphomannomutase 2-congenital disorders of glycosylation (PMM2-CDG) is part of the multisystemic presentation contributing to high mortality rates. The most common cardiac manifestations are pericardial effusion, cardiomyopathy, and structural heart defects. A genotype-phenotype correlation with organ involvement has not yet been described. We analyzed clinical, biochemical, and molecular genetic data of 222 patients from eight European centers and characterized the natural course of patients with CI. Fifty-seven patients (45 children) presented with CI, of whom 24 died (median age 21 months, standard deviation 49.8). Pericardial effusion was the most frequent manifestation (55.4%), occurring mostly within the first 6 months of life. The most common pathogenic variants in patients with CI were p.(Arg141His) in 74%, followed by p.(Val231Met) in 36%, which is 3.5 times higher than in PMM2-CDG patients without CI (p < 0.0001). Twenty-one out of 36 patients with p.(Val231Met) had CI; among them, 15 died, compared to 33 out of 166 patients without p.(Val231Met) who had CI (p < 0.0001). Nine out of 33 patients died (p = 0.0015), indicating greater clinical severity. Furthermore, the p.(Val231Met) variant is predominant in Eastern Europe, suggesting a founder effect. Cardiac complications in PMM2-CDG patients are common and serious. The variant p.(Val231Met) profoundly influences the extent of CI and mortality rates. Therefore, we recommend cardiac surveillance be included in the follow-up protocols for PMM2-CDG.

Child Neuropsychiatry Department of Clinical and Experimental Medicine University of Catania Catania Italy

Children's Clinic Tartu University Hospital Tartu Estonia

Department of Clinical Genetics Genetics and Personalized Medicine Clinic Tartu University Hospital Tartu Estonia

Department of Development and Regeneration KU Leuven Leuven Belgium

Department of Human Genetics and Neurology Translational Metabolic Laboratory Donders Center for Brain Cognition and Behavior Radboud University Medical Center Nijmegen The Netherlands

Department of Inborn Errors of Metabolism and Paediatrics Institute of Mother and Child Warsaw Poland

Department of Internal Medicine Radboud University Medical Centre Nijmegen The Netherlands

Department of Paediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Paediatrics and Metabolic Center University Hospitals Leuven Leuven Belgium

Department of Pediatrics Milano Bicocca University San Gerardo Hospital Monza Italy

Division of Metabolism Bambino Gesù Children's Research Hospital Rome Italy

Institute of Clinical Medicine University of Tartu Tartu Estonia

Metabolic Unit Great Ormond Street Hospital and Institute of Child Health University College London NHS Trust London UK

Neurology Department Hospital Sant Joan de Déu U 703 Centre for Biomedical Research on Rare Diseases Instituto de Salud Carlos 3 Barcelona Spain

Oasi Research Institute IRCCS Troina Italy

One Day Clinic The Institute of Mother and Child Warsaw Poland

Tallinn Children's Hospital Tallinn Estonia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002858
003      
CZ-PrNML
005      
20250206103917.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12826 $2 doi
035    __
$a (PubMed)39633515
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Holubova, Veronika $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
245    10
$a Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations / $c V. Holubova, R. Barone, S. Grunewald, M. Tesařová, H. Hansíková, J. Augustínová, J. Sykut-Cegielska, F. De Nictolis, U. Diaz-Moreno, R. Elangovan, F. Epifani, S. Gasperini, M. Jansen, D. Lefeber, D. Maksym-Gasiorek, M. Diego, K. Ounap, F. Pettinato, H. Põder, D. Rymen, MA. Vals, M. Serrano, P. Witters, T. Honzík
520    9_
$a Cardiac involvement (CI) in phosphomannomutase 2-congenital disorders of glycosylation (PMM2-CDG) is part of the multisystemic presentation contributing to high mortality rates. The most common cardiac manifestations are pericardial effusion, cardiomyopathy, and structural heart defects. A genotype-phenotype correlation with organ involvement has not yet been described. We analyzed clinical, biochemical, and molecular genetic data of 222 patients from eight European centers and characterized the natural course of patients with CI. Fifty-seven patients (45 children) presented with CI, of whom 24 died (median age 21 months, standard deviation 49.8). Pericardial effusion was the most frequent manifestation (55.4%), occurring mostly within the first 6 months of life. The most common pathogenic variants in patients with CI were p.(Arg141His) in 74%, followed by p.(Val231Met) in 36%, which is 3.5 times higher than in PMM2-CDG patients without CI (p < 0.0001). Twenty-one out of 36 patients with p.(Val231Met) had CI; among them, 15 died, compared to 33 out of 166 patients without p.(Val231Met) who had CI (p < 0.0001). Nine out of 33 patients died (p = 0.0015), indicating greater clinical severity. Furthermore, the p.(Val231Met) variant is predominant in Eastern Europe, suggesting a founder effect. Cardiac complications in PMM2-CDG patients are common and serious. The variant p.(Val231Met) profoundly influences the extent of CI and mortality rates. Therefore, we recommend cardiac surveillance be included in the follow-up protocols for PMM2-CDG.
650    _2
$a lidé $7 D006801
650    12
$a fosfotransferasy (fosfomutasy) $x genetika $x nedostatek $7 D017875
650    12
$a vrozené poruchy glykosylace $x genetika $7 D018981
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kojenec $7 D007223
650    _2
$a předškolní dítě $7 D002675
650    12
$a fenotyp $7 D010641
650    _2
$a dítě $7 D002648
650    _2
$a novorozenec $7 D007231
650    _2
$a mladiství $7 D000293
650    _2
$a mutace $7 D009154
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a kardiomyopatie $x genetika $7 D009202
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Barone, Rita $u Child Neuropsychiatry-Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy $u Oasi Research Institute-IRCCS, Troina, Italy
700    1_
$a Grunewald, Stephanie $u Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, NHS Trust, London, UK
700    1_
$a Tesařová, Markéta $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Hansíková, Hana $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Augustínová, Jana $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Sykut-Cegielska, Jolanta $u Department of Inborn Errors of Metabolism and Paediatrics, Institute of Mother and Child, Warsaw, Poland
700    1_
$a De Nictolis, Francesca $u Division of Metabolism, Bambino Gesù Children's Research Hospital, Rome, Italy
700    1_
$a Diaz-Moreno, Unai $u Neurology Department, Hospital Sant Joan de Déu, U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain
700    1_
$a Elangovan, Ramyia $u Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, NHS Trust, London, UK
700    1_
$a Epifani, Florencia $u Neurology Department, Hospital Sant Joan de Déu, U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain
700    1_
$a Gasperini, Serena $u Department of Pediatrics, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy
700    1_
$a Jansen, Mirian $u Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands
700    1_
$a Lefeber, Dirk $u Department of Human Genetics and Neurology, Translational Metabolic Laboratory, Donders Center for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Maksym-Gasiorek, Dorota $u One Day Clinic, The Institute of Mother and Child, Warsaw, Poland
700    1_
$a Diego, Martinelli $u Division of Metabolism, Bambino Gesù Children's Research Hospital, Rome, Italy
700    1_
$a Ounap, Katrin $u Institute of Clinical Medicine, University of Tartu, Tartu, Estonia $u Department of Clinical Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia
700    1_
$a Pettinato, Fabio $u Child Neuropsychiatry-Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
700    1_
$a Põder, Haide $u Tallinn Children's Hospital, Tallinn, Estonia
700    1_
$a Rymen, Daisy $u Department of Paediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Vals, Mari-Anne $u Institute of Clinical Medicine, University of Tartu, Tartu, Estonia $u Children's Clinic, Tartu University Hospital, Tartu, Estonia
700    1_
$a Serrano, Mercedes $u Neurology Department, Hospital Sant Joan de Déu, U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain $1 https://orcid.org/0000000220562428
700    1_
$a Witters, Peter $u Department of Paediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium $u Department of Development and Regeneration, KU Leuven, Leuven, Belgium
700    1_
$a Honzík, Tomáš $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000343002519 $7 xx0075651
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 48, č. 1 (2025), s. e12826
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39633515 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103913 $b ABA008
999    __
$a ok $b bmc $g 2262950 $s 1238865
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 48 $c 1 $d e12826 $e 20241205 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
GRA    __
$a AZV MZ CR NU22-07-00474 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a RVO-VFN 64165 $p Všeobecná Fakultní Nemocnice v Praze
GRA    __
$p lékařská fakulta Univerzity Karlovy COOPERATIO-Pediatrics
GRA    __
$a PI14/00021 $p Ministerio de Ciencia e Innovación
GRA    __
$a PI21/00068 $p Ministerio de Ciencia e Innovación
GRA    __
$a FI22/00218 $p Ministerio de Ciencia e Innovación
GRA    __
$a G049220N $p Fonds Wetenschappelijk Onderzoek
GRA    __
$a Fundamenteel Klinisch Mandaat 18B4322N $p Fonds Wetenschappelijk Onderzoek
GRA    __
$a PRG471 $p Eesti Teadusagentuur
GRA    __
$a PRG2040 $p Eesti Teadusagentuur
GRA    __
$a Prot. 202255RLB4 $p Agenzia Italiana del Farmaco, Ministero della Salute
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace